Aktis Oncology $318 million IPO
This is the first biotech IPO of 2026
Experience
To find Davis Polk deals and cases of particular interest, select filters based on practice, industry, region, lawyer and keyword.
Filters
Beacon Therapeutics $75 million Series C financing round
We advised Forbion on its participation in the financing round
InSilico Medicine HK$2.62 billion IPO
We advised InSilico Medicine on its IPO and HKEX listing
PegBio HK$300 million placement of shares
We advised PegBio on the placement of new shares
Kodiak Sciences $184 million stock offering
We advised the underwriters on the offering
Zoetis $2 billion convertible senior notes offering
We advised the representatives of the initial purchasers on the offering
Tenaya Therapeutics $60 million units offering
We advised the joint book-running managers and representatives of the several underwriters
Sevita $1.275 billion notes offering
We advised the representative of the initial purchasers on the offering
Terns Pharmaceuticals $747.5 million stock offering
We advised the underwriters on the public offering
Biocytogen RMB1.27 billion Shanghai IPO
We advised Biocytogen on its IPO and SSE listing